| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
Quinlan Paul T serves as a General Counsel at ORKA. Across recent SEC filings that breaks down to 0 buys and 12 sells. Those positions are worth an estimated $3.4M at current prices.
The biggest single holding is ORKA (~$3.4M) as General Counsel. The recent filings there lean toward selling, a net 63,772 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | ORKA Oruka Therapeutics, Inc. | General Counsel | Sale+OE | 10,000 | $93.64 | $936,417.48 | -25.0% | |
| Sep 15, 2026 | ORKA Oruka Therapeutics, Inc. | General Counsel | Sell | 1,039 | $95.71 | $99,442.69 | -3.3% | |
| Aug 14, 2026 | ORKA Oruka Therapeutics, Inc. | General Counsel | Sale+OE | 52,000 | $108.49 | $5,641,408.94 | -62.6% | |
| Jun 15, 2026 | ORKA Oruka Therapeutics, Inc. | General Counsel | Sell | 733 | $69.69 | $51,082.77 | -2.3% |